Paula S Römer Selected Research

TGN-1412 (TGN1412)

7/2016	From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis.
4/2014	Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
3/2014	Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response.
12/2011	Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paula S Römer Research Topics

Disease

4	Cytokine Release Syndrome 07/2016 - 12/2011
2	Rheumatoid Arthritis 07/2016 - 04/2014
1	Inflammation (Inflammations) 07/2016

Drug/Important Bio-Agent (IBA)

4	TGN-1412 (TGN1412)IBA 07/2016 - 12/2011
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2014
1	CytokinesIBA 04/2014
1	Monoclonal AntibodiesIBA 12/2011

Therapy/Procedure

1	Therapeutics 07/2016
1	Transplantation 07/2016